Trial Profile
Young colorectal cancer patients with liver-only disease treated with upfront CAPOX and Bevacizumab combination – Single institution experience
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- 06 Oct 2015 New trial record